Poor
Partially Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely do not align with the FDA-approved label. A substantial portion of statements are not supported by the label, and a minority are contradicted. There are multiple off-label or non-labeled assertions and several missing label-specific details.
Category Scores
Accurate Statements
Drowsiness is a common side effect of gabapentin.
5.4
Drowsiness affects up to 21% of users in clinical studies.
5.4
Drowsiness is often listed as somnolence.
5.4
Drowsiness is more likely when starting treatment or increasing doses.
5.4
In placebo-controlled trials, somnolence occurred in 19% of patients on gabapentin.
5.4
In placebo-controlled trials, somnolence occurred in 5-7% of patients on placebo.
5.4
Higher doses (1,800-3,600 mg/day) increase the risk of drowsiness.
5.4
Persistent drowsiness may signal overdose.
10
Persistent drowsiness may signal interactions with opioids or alcohol.
7.1, 5.3
Dose reduction may help.
2.3
Severe cases need medical attention.
5.4
People with epilepsy or kidney issues have higher risk of gabapentin drowsiness.
5.4, 2.3
Avoid driving or operating machinery until effects stabilize.
5.3
Gabapentin drowsiness is around 20%.
5.4
Gabapentin is used off-label for sleep issues partly due to this sedative effect.
12.1
Gabapentin half-life is around 5-7 hours.
12.3
Unsupported Statements
Drowsiness can range from mild sleepiness to significant fatigue.
Not explicit wording in label; described as somnolence with specific terminology in the adverse events.
Drowsiness typically starts within the first few days.
Onset timing not specified in label.
Drowsiness may lessen over time as the body adjusts.
No explicit statement about time course in label.
Gabapentin acts on voltage-gated calcium channels in the brain, reducing excitatory neurotransmitter release.
Label describes binding to the α2δ subunit; relationship to therapeutic effect not definitively stated as reducing neurotransmitter release.
Gabapentin has a calming effect, similar to GABA but without direct binding.
Label states gabapentinoid mechanism but does not characterize as calming or as GABA-mimetic without binding.
This slows neural activity, leading to sedation.
Not described as a mechanism in label.
Gabapentin is used off-label for sleep issues partly due to this sedative effect.
Off-label use for sleep is not described in label.
Drowsiness peaks 2-3 hours after dosing.
Onset timing not specified in label.
Extended-release formulations may cause less daytime sleepiness.
Not stated in label.
Taking gabapentin at night reduces next-day impact.
Not stated in label.
Renal impairment slows clearance signaling drowsiness correlation.
No explicit statement linking drowsiness to renal impairment in label.
Splitting doses may help.
Not explicitly stated in label.
Switching to pregabalin may help (less sedating for some).
Not described in gabapentin labeling.
Elderly patients have a doubled risk of gabapentin drowsiness.
Label does not quantify doubled risk; provided as CONTRAINDICATED in the evaluation.
New users report higher rates of drowsiness.
Not stated in label.
Children under 12 have drowsiness rates of about 15%.
Pediatric drowsiness data exist but exact rate ~15% is not provided in label snippet.
Women may notice drowsiness slightly more than men.
No sex-based differential rate stated in labeling.
Start low and titrate slowly to manage drowsiness.
Dosing guidance exists (renal adjustments); exact phrasing not in label.
Caffeine may help mildly.
Not mentioned in label.
Short naps may help mildly.
Not mentioned in label.
Do not combine gabapentin with sedatives.
Label notes CNS depressants interactions but not a strict prohibition; nuance present.
About 10% discontinue due to drowsiness.
Discontinuation rate due to drowsiness not explicitly stated in label.
Pregabalin drowsiness is around 15-18%.
Pregabalin is a different drug; label pertains to gabapentin.
Topiramate has less drowsiness (~8%), but more cognitive fog.
Not part of gabapentin labeling.
Lamotrigine rarely causes drowsiness (<5%).
Not part of gabapentin labeling.
Contradictions
Low
AI Statement
Elderly patients have a doubled risk of gabapentin drowsiness.
Label Reference
8
Low
AI Statement
About 10% discontinue due to drowsiness.
Label Reference
5.4
Important Omissions
Boxed warning for suicidality
Importance:
High
Pregnancy risk information
Importance:
High
Pediatric safety specifics (rates, age-specific data)
Importance:
Moderate
Explicit interaction guidance with CNS depressants beyond opioids/alcohol
Importance:
Moderate
Explicit onset timing for drowsiness
Importance:
Moderate
Explicit line-item guidance on dosing timing (night dosing benefits on next-day sleepiness)
Importance:
Moderate
Exact discontinuation rate due to drowsiness
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
While several statements discuss adverse events and interactions, the overall alignment is poor due to many off-label and unsupported claims; the risk to a reader is primarily informational misalignment rather than direct clinical danger.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Large portion of claims are not supported by the label; several off-label and potentially misleading statements.
Suggested Improvement
Limit content strictly to FDA-approved labeling; cite exact label sections for each claim; avoid extrapolations about off-label uses, onset timing, and non-labeled rates. Include comprehensive, label-backed dosing and safety guidance.